These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

95 related items for PubMed ID: 24775731

  • 1. Emerging therapies in castration resistant prostate cancer.
    Thoreson GR, Gayed BA, Chung PH, Raj GV.
    Can J Urol; 2014 Apr; 21(2 Supp 1):98-105. PubMed ID: 24775731
    [Abstract] [Full Text] [Related]

  • 2. Castration-resistant prostate cancer: from new pathophysiology to new treatment.
    Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, Sartor O, Saad F.
    Eur Urol; 2014 Feb; 65(2):289-99. PubMed ID: 23957948
    [Abstract] [Full Text] [Related]

  • 3. Current management of advanced and castration resistant prostate cancer.
    Gomella LG, Petrylak DP, Shayegan B.
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [Abstract] [Full Text] [Related]

  • 4. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).
    Tsao CK, Galsky MD, Small AC, Yee T, Oh WK.
    BJU Int; 2012 Dec; 110(11):1580-8. PubMed ID: 22985411
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. New therapies for castration-resistant prostate cancer: efficacy and safety.
    Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF.
    Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
    [Abstract] [Full Text] [Related]

  • 7. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
    Bastos DA, Dzik C, Rathkopf D, Scher HI.
    Oncology (Williston Park); 2014 Aug; 28(8):693-9. PubMed ID: 25140626
    [Abstract] [Full Text] [Related]

  • 8. Novel agents for the management of castration-resistant prostate cancer.
    Haddad H, Garcia JA.
    Curr Opin Urol; 2012 May; 22(3):175-82. PubMed ID: 22472509
    [Abstract] [Full Text] [Related]

  • 9. The E2F1/DNMT1 axis is associated with the development of AR negative castration resistant prostate cancer.
    Valdez CD, Kunju L, Daignault S, Wojno KJ, Day ML.
    Prostate; 2013 Dec; 73(16):1776-85. PubMed ID: 24038143
    [Abstract] [Full Text] [Related]

  • 10. Current, new and novel therapy for castration-resistant prostate cancer.
    Gaya JM, Ahallal Y, Sanchez-Salas R, Barret E, Rozet F, Galiano M, Macek P, Durand M, Cerruti J, Prapotnich D, Ropert S, Bennamoun M, Cathelineau X.
    Expert Rev Anticancer Ther; 2013 Jul; 13(7):819-27. PubMed ID: 23875660
    [Abstract] [Full Text] [Related]

  • 11. The future of systemic therapies for localised prostate cancer.
    Eigl BJ, Gleave ME, Chi KN.
    Clin Oncol (R Coll Radiol); 2013 Aug; 25(8):506-13. PubMed ID: 23660300
    [Abstract] [Full Text] [Related]

  • 12. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
    Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, Alcaraz A, Bahl A, Bracarda S, Di Lorenzo G, Efstathiou E, Finn SP, Fosså S, Gillessen S, Kellokumpu-Lehtinen PL, Lecouvet FE, Oudard S, de Reijke TM, Robson CN, De Santis M, Seruga B, de Wit R.
    Eur J Cancer; 2014 Jun; 50(9):1617-27. PubMed ID: 24703899
    [Abstract] [Full Text] [Related]

  • 13. Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.
    Cereda V, Formica V, Massimiani G, Tosetto L, Roselli M.
    Expert Opin Investig Drugs; 2014 Apr; 23(4):469-87. PubMed ID: 24490883
    [Abstract] [Full Text] [Related]

  • 14. Progress in emerging therapies for advanced prostate cancer.
    Oudard S.
    Cancer Treat Rev; 2013 May; 39(3):275-89. PubMed ID: 23107383
    [Abstract] [Full Text] [Related]

  • 15. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer.
    Rove KO, Crawford ED.
    Curr Opin Urol; 2013 May; 23(3):208-13. PubMed ID: 23492838
    [Abstract] [Full Text] [Related]

  • 16. How to approach sequencing therapy in patients with metastatic castration resistant prostate cancer.
    Dreicer R.
    Can J Urol; 2014 Apr; 21(2 Supp 1):93-7. PubMed ID: 24775730
    [Abstract] [Full Text] [Related]

  • 17. Emerging therapies targeting castration-resistant prostate cancer.
    Gkialas IK, Fragkoulis C.
    J BUON; 2015 Apr; 20(6):1389-96. PubMed ID: 26854432
    [Abstract] [Full Text] [Related]

  • 18. Emerging therapies in castrate-resistant prostate cancer.
    Lassi K, Dawson NA.
    Curr Opin Oncol; 2009 May; 21(3):260-5. PubMed ID: 19363343
    [Abstract] [Full Text] [Related]

  • 19. Practical guide to the use of chemotherapy in castration resistant prostate cancer.
    Petrylak DP.
    Can J Urol; 2014 Apr; 21(2 Supp 1):77-83. PubMed ID: 24775728
    [Abstract] [Full Text] [Related]

  • 20. [Current status and future direction of the treatment of CRPC (castration resistant prostate cancer)].
    Akaza H.
    Nihon Rinsho; 2014 Dec; 72(12):2108-15. PubMed ID: 25518342
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.